The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Foundation Medicine gets genomic profiling contract from Veterans Affairs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Foundation Medicine Inc. announced a nationwide contract with the U.S. Department of Veterans Affairs National Precision Oncology Program to provide comprehensive genomic profiling for eligible Veterans with advanced cancer.

The contract covers all of Foundation Medicine’s available tests, including FoundationOne CDx and FoundationOne Liquid for solid tumors, as well as FoundationOne Heme for hematologic malignancies.

“Foundation Medicine is honored to be awarded a contract to provide comprehensive genomic profiling for veterans with advanced cancer,” Cindy Perettie, chief executive officer at Foundation Medicine, said in a statement. “This decision by the VA as well as Medicare’s National Coverage Determination issued in early 2018 mark important steps forward in access to personalized cancer care.”

Table of Contents

YOU MAY BE INTERESTED IN

Book Review

What are The CheckPoints movin’ and groovin’ to this summer?
Join the journal club with the best bops: We asked SITC’s 13-piece band of medical musicians for the top papers and songs of the summer

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
By Sara Willa Ernst and Paul Goldberg
Guest Editorial

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion

At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
By Richard L. Schilsky, H. Kim Lyerly, Thomas R. Fleming and Renzo Canetta
ClinicalGuest Editorial

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 
By Viktor Clark, Sean M. Dozier, AnnaLynn M. Williams, Cynthia M. Rand and Lee A. Kehoe
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account